CDMO partnerships and manufacturing scaling continued to target higher-complexity modalities. Forge Bio announced a manufacturing collaboration with Restore Vision for RV-001, an AAV-based gene therapy for retinitis pigmentosa. The deal covers AAV process development and clinical GMP manufacturing, with clinical supply support for Restore Vision’s Phase I/II program in Japan. In parallel, Celonic and Leukocare expanded CDMO capabilities for complex biologics by combining Celonic’s upstream and GMP manufacturing services with Leukocare’s data science-driven drug product development expertise. The collaboration is aimed at modalities such as bispecific and multispecific antibodies and high-concentration formulations. These moves highlight ongoing efforts to de-risk manufacturing timelines and increase comparability for advanced biologics entering clinic.